Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.09.17.676427

Cancer-Testis Antigens as Clinical and Prognostic Biomarkers in Gastric Adenocarcinoma: Integration of Differential Expression, Clinical Associations, Survival, and Co-Expression Networks

Abstract

Gastric adenocarcinoma (GAC) remains one of the leading causes of cancer-related mortality, characterized by marked molecular and clinical heterogeneity, which underscores the need for robust biomarkers. In this study, we aimed to evaluate the role of cancer-testis antigens (CTAs) in GAC through integrated analyses of differential expression, clinical associations, survival impact, and gene co-expression networks. The cohort included 156 patients with complete clinical data, comprising a total of 362 tissue samples (tumor, peritumoral, and metaplastic). We identified 541 differentially expressed genes, of which 49 corresponded to previously described CTAs. Between GAC and peritumoral tissues, 14 CTAs exhibited significant differential expression, with MAGEA3, MAGEA6, GOLGA6L1, and MAGEA2 among the most highly expressed in tumors. Relevant associations were observed between the expression of MAGEA3, MAGEA6, POTEF, and CTCFL with TNM staging, as well as IGF2BP1, DAZ1/3/4, YBX2, and PCDHA4 in relation to variables such as tumor depth, metastasis, and TCGA subtypes. Survival analysis demonstrated that high expression of IGF2BP1, CTCFL, CT45A5, and LIN28B was strongly associated with worse prognosis (HR > 2.7), whereas SYCE1L, PIK3R3, and ZNF683 showed a protective effect. The co-expression network revealed five main clusters, highlighting germline-related modules (MAGEA, DAZ, CSAG), adhesion and transcriptional regulation (YBX2, POTEF, PCDHA, TAF1L), and immune-related genes (IRAK3, CXCR1, PIK3R3), evidencing functional integration between proliferation, adhesion, and immune microenvironment modulation. Collectively, these findings reinforce CTAs as potential clinical and prognostic biomarkers in GAC, with direct implications for risk stratification and the development of personalized therapeutic strategies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Valente, J. D., Marques, L. E. C., Mourao, R. M. d. S., Rodrigues, B. d. F. d. R., de Souza, L. S., da Silva, J. M. C., Demachki, S., Ishak, G., Moreira, F., Casseb, S. M. M., Burbano, R. M. R., Assumpcao, P. P.. 2025-09-20. Cancer-Testis Antigens as Clinical and Prognostic Biomarkers in Gastric Adenocarcinoma: Integration of Differential Expression, Clinical Associations, Survival, and Co-Expression Networks. https://doi.org/10.1101/2025.09.17.676427

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗